Indication: Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic L
An Open-Label, Multicenter Study of RC-P in Patients with Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) Following Hypersensitivity to E. coli-derived Asparaginases
Sub-indication: Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic L
Study Type: Drug Study
Principal Investigator: Ashok Raj, M.D.Norton Children's Cancer Institute, affiliated with the UofL School of Medicine
Sponsor: Sponsor: Jazz Pharmaceuticals
